📊 BIIB Key Takeaways
Is Biogen Inc.. (BIIB) a Good Investment?
Biogen maintains solid financial health with exceptional free cash flow ($594.3M) and fortress-like balance sheet (3.06x current ratio, 0.34x leverage), providing stability and flexibility. However, deteriorating profitability (-20.8% net income YoY) coupled with critically low returns on capital (1.7% ROE, 1.1% ROA) despite modest 2.2% revenue growth signals operational challenges that offset balance sheet strength.
Biogen shows solid fundamental stability with strong free cash flow generation, healthy liquidity, and manageable leverage, which supports financial resilience. However, growth quality looks mixed: revenue growth is modest, net income is flat, diluted EPS declined sharply, and the reported gross margin above 100% suggests either unusual accounting dynamics or data-quality distortion that reduces clarity around underlying profitability.
Biogen Inc.. Key Strengths (BIIB)
- Outstanding free cash flow generation of $594.3M with 24% FCF margin demonstrates cash earning power
- Excellent liquidity with 3.06x current ratio and 2.41x quick ratio provides substantial financial flexibility
- Conservative leverage at 0.34x debt-to-equity with $3.4B cash position ensures low financial distress risk
- Adequate interest coverage of 5.6x supports debt servicing capacity
- Positive $645.5M operating cash flow indicates core business cash generation capability
- Strong free cash flow generation with a 20.7% FCF margin and low capital intensity
- Healthy balance sheet with 2.68x current ratio, 2.03x quick ratio, and moderate 0.34x debt-to-equity
- Positive top-line growth and continued profitability with $1.29B net income and $2.20B operating cash flow
BIIB Stock Risks: Biogen Inc.. Investment Risks
- Net income declined 20.8% YoY while revenue grew only 2.2%, signaling severe margin compression or one-time charges
- Diluted EPS fell 21.4% YoY, destroying shareholder value despite positive cash generation
- Critically depressed ROE (1.7%) and ROA (1.1%) indicate extremely poor capital efficiency and returns on $18.7B equity base
- Anemic 2.2% revenue growth in biotech sector suggests pipeline challenges, patent cliffs, or competitive pressures
- Operating margin of 15.2% under pressure; further deterioration could threaten cash flow sustainability
- Growth is modest, with revenue up only 2.2% year over year and net income essentially flat
- Diluted EPS fell 21.4% year over year, signaling weaker per-share earnings quality
- Reported gross margin of 117.7% is anomalous and raises concern about metric reliability or nonrecurring accounting effects
Key Metrics to Watch
- Net income and EPS trajectory - stabilization or continued decline is critical to investment thesis
- Return on Equity - must demonstrate improvement from severely depressed 1.7% level
- Revenue growth acceleration - needs to exceed 2.2% to indicate pipeline strength and market position
- Operating margin trends - compression suggests cost structure misalignment with revenue base
- Operating margin and net income conversion from revenue growth
- Diluted EPS trend relative to net income and free cash flow
Biogen Inc.. (BIIB) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 24.0% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 3.06x current ratio provides a solid financial cushion.
BIIB Profit Margin, ROE & Profitability Analysis
BIIB vs Healthcare Sector: How Biogen Inc.. Compares
How Biogen Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Biogen Inc.. Stock Overvalued? BIIB Valuation Analysis 2026
Based on fundamental analysis, Biogen Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Biogen Inc.. Balance Sheet: BIIB Debt, Cash & Liquidity
BIIB Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Biogen Inc..'s revenue has declined by 31% over the 5-year period, indicating business contraction. The most recent EPS of $7.97 reflects profitable operations.
BIIB Revenue Growth, EPS Growth & YoY Performance
BIIB Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $2.4B | $240.5M | $1.64 |
| Q3 2025 | $2.5B | $388.5M | $2.66 |
| Q2 2025 | $2.5B | $583.6M | $4.00 |
| Q1 2025 | $2.3B | $240.5M | $1.64 |
| Q3 2024 | $2.5B | -$68.1M | $-0.47 |
| Q2 2024 | $2.5B | $583.6M | $4.00 |
| Q1 2024 | $2.3B | $387.9M | $2.67 |
| Q3 2023 | $2.5B | -$68.1M | $-0.47 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Biogen Inc.. Dividends, Buybacks & Capital Allocation
BIIB SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Biogen Inc.. (CIK: 0000875045)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BIIB
What is the AI rating for BIIB?
Biogen Inc.. (BIIB) has a Combined AI Grade of B from Claude (B) and ChatGPT (B) with 72% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BIIB's key strengths?
Claude: Outstanding free cash flow generation of $594.3M with 24% FCF margin demonstrates cash earning power. Excellent liquidity with 3.06x current ratio and 2.41x quick ratio provides substantial financial flexibility. ChatGPT: Strong free cash flow generation with a 20.7% FCF margin and low capital intensity. Healthy balance sheet with 2.68x current ratio, 2.03x quick ratio, and moderate 0.34x debt-to-equity.
What are the risks of investing in BIIB?
Claude: Net income declined 20.8% YoY while revenue grew only 2.2%, signaling severe margin compression or one-time charges. Diluted EPS fell 21.4% YoY, destroying shareholder value despite positive cash generation. ChatGPT: Growth is modest, with revenue up only 2.2% year over year and net income essentially flat. Diluted EPS fell 21.4% year over year, signaling weaker per-share earnings quality.
What is BIIB's revenue and growth?
Biogen Inc.. reported revenue of $2.5B.
Does BIIB pay dividends?
Biogen Inc.. does not currently pay dividends.
Where can I find BIIB SEC filings?
Official SEC filings for Biogen Inc.. (CIK: 0000875045) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BIIB's EPS?
Biogen Inc.. has a diluted EPS of $2.15.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is BIIB's fundamental grade?
Based on our AI fundamental analysis in June 2026, Biogen Inc.. has a B grade with 72% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is BIIB stock overvalued or undervalued?
Valuation metrics for BIIB: ROE of 1.7% (sector avg: 15%), net margin of 12.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is BIIB's AI grade for 2026?
Our dual AI analysis gives Biogen Inc.. a combined B grade for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is BIIB's free cash flow?
Biogen Inc..'s operating cash flow is $645.5M, with capital expenditures of $51.2M. FCF margin is 24.0%.
How does BIIB compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 12.9% (avg: 12%), ROE 1.7% (avg: 15%), current ratio 3.06 (avg: 2).